Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI to predict heart attacks in diabetes patients: qatar study

NCT ID NCT07515807

First seen Apr 10, 2026 · Last updated Jun 20, 2026 · Updated 8 times

Summary

This study will look at health records of 10,000 patients in Qatar who were hospitalized for heart problems and have diabetes or prediabetes. Researchers will use artificial intelligence to find patterns that predict future heart attacks, strokes, or death. The goal is to create better risk prediction tools for this high-risk group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hamad Medical Corporation

    Doha, Qatar

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to better risk prediction tools for heart attacks and strokes in people with diabetes, helping doctors intervene earlier.

What could go wrong

This is an observational study using existing data, so it cannot prove cause and effect. The AI models may not work well for people outside Qatar or other Arab populations.

Conditions

The condition(s) this trial relates to.

acute coronary syndrome cardiovascular disorder glucose intolerance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.